RNS Number : 4246O
Wilmcote Holdings PLC
02 October 2019

2 October 2019
This announcement contains inside information

Wilmcote Holdings plc

Statement regarding potential acquisition
Wilmcote Holdings Plc ("Wilmcote" or the "Company") announces that further to the statements made on 4 June 2019 and 18 July 2019, it has evaluated a range of transaction structures regarding the potential acquisition of US-based speciality chemicals business, Arclin Inc ("Arclin"). The Company will not be pursuing a direct acquisition for Arclin by Wilmcote, however the Company remains interested in indirectly participating in a possible acquisition of Arclin by an unaffiliated US-listed investment vehicle. It is anticipated a successful transaction will result in the Wilmcote management group being engaged by the unaffiliated US-listed investment vehicle and is expected to include provision for Wilmcote to receive compensation to reflect its investment in the acquisition opportunity.

Whilst there can be no certainty of a successful transaction, the Board believe that this approach is the most likely way of creating shareholder value through a successful acquisition of Arclin by an unaffiliated US-listed investment vehicle.

Given the continued uncertainty over the transaction structure and financial impact to Wilmcote and its shareholders, Wilmcote's ordinary shares remain suspended pending a further announcement in relation to this transaction.

Teneo (Financial PR)
Tel: +44 (0) 7703 330 269
Charles Armitstead

Numis Securities Limited (Nominated Adviser and Broker)
Tel: +44 (0) 20 7260 1000
Kevin Cruickshank
Jamie Loughborough

Adrian Whitfield is Chief Executive Officer of Wilmcote Holdings plc, which has its offices at 11 Buckingham Street, London, WC2N 6DF and has the LEI number 2138004EUUU11OVHZW75.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

STREAPEFEFXNFFF